VEGF in Iris Tissue in Primary Congenital Glaucoma

NCT05484050 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-08-02

No results posted yet for this study

Summary

Estimation of vascular endothelial growth factor (VEGF) in iris tissue specimen in primary congenital glaucoma through Immunohistochemistry.

Conditions

  • Iris

Interventions

OTHER

Immunohistochemistry analysis

Estimation of VEGF through Immunohistochemistry

Sponsors & Collaborators

  • Hassan Lotfy Fahmy

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Day
Max Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2023-03-31
Completion
2023-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05484050 on ClinicalTrials.gov